The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...